As Attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported strong Q1 FY26 results with revenue from operations rising about 70% year-on-year to ₹539.11 lakhs (vs ₹317.80 lakhs in Q1 FY25). Total income grew to ₹650.08 lakhs from ₹389.56 lakhs. Net profit more than doubled to ₹102.96 lakhs from ₹48.53 lakhs, translating to EPS of ₹0.02 (face value reduced from ₹10 to ₹1 per share). Total expenses rose to ₹512.78 lakhs, broadly in line with the scale-up in operations. The auditor (MAAK and Associates) issued an unqualified limited review report with no qualifications, qualifications, or emphasis of matter.
Sharp revenue and profit growth signal strong business momentum, which is positive for shareholders. The face value split (₹10 → ₹1) improves share liquidity, making the stock more accessible to retail investors. Investors should watch if this growth trajectory sustains through the rest of FY26.